Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29    OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Penafian: Artikel ini diterbitkan semula dari media lain. Tujuan mencetak semula adalah untuk menyampaikan lebih banyak maklumat. Ini tidak bermakna laman web ini bersetuju dengan pandangannya dan bertanggungjawab ke atas keasliannya, dan tidak menanggung tanggungjawab undang-undang. Semua sumber di laman web ini dikumpulkan di Internet. Tujuan perkongsian adalah untuk pembelajaran dan rujukan sahaja. Sekiranya terdapat pelanggaran hak cipta atau harta intelek, sila tinggalkan mesej.

Terbaru

  • Official meeting between Xi Jinping and Biden attracts attention

    The highlight of the G20 must be a 3-hour meeting between President Xi and President Biden but there were a few other important points to take away first.
  • Shaoxing Famous Products Fabric&App Industry (RCEP)INTL Trade Online Exhibition 2022

    Shaoxing Famous Products Fabric &APP Industry (RCEP) INTL Trade Online Exhibition 2022 is a professional online exhibition hosted by the Shaoxing Municipal Commerce Bureau, the CCPIT Shaoxing, the Shaoxing Chamber of International Commerce and undertaken by Shaoxing Boda Business Exhibition Co.,Ltd. The exhibition relies on "Shaoxing Online Exhibition Platform" and Zoom to display enterprise products, and conducts one-to-one accurate matching and online negotiation with buyers from RCEP Countries.
  • FastData Released the First TikTok Ecological Industry Report

    On September 16, the 2022 Global Short Video Summit hosted by FastData came to a successful conclusion. At the summit, many entrepreneurs from the forefront of TikTok's business ecology shared a lot of contents and insights. Meanwhile the TikTok Ecological Sky Eye Award for the first half of FastData was given at the summit.
  • Pengkomputeran ialah P produktiviti. UtilityNet Mengubah Pengkomputeran daripada Teknologi Kepada Insentif .

    "Pengkomputeran ialah kuasa produktif pertama ekonomi digital . " Pada 29 Julai 2022, di Subforum Sains dan Teknologi SenseTime bagi Persidangan Pengkomputeran Pertama di China, Gao Shanshan, pengarah Pusat Penyelidikan Kerjasama Antarabangsa Media Digital AS Shandong Sino berkata, dalam era AI, infrastruktur pengkomputeran terus mengubah industri seperti kewangan, perubatan dan pusat data.
  • The Grand Opening of China International Huangjiu Industry Expo 2022 & 28th Shaoxing Huangjiu Festival

    On November 7th , China International Huangjiu Industry Expo 2022 and the 28th Shaoxing Huangjiu Festival were grand opening in Shaoxing Huangjiu town, Zhejiang Province. The Event are organized by China Alcoholic Drinks Association (CADA) and Shaoxing Municipal People’s Government. More than 100 Huangjiu companies and 1000 products participated in the exhibition. Opening Ceremony, China Huangjiu Development Forum, China Huangjiu International Exchange Summit 2022,China Huangjiu New Media (Digital Marketing) Forum were held At the same time.
  • Global Economic downturn, these signals need to be focused on

    In the World Economic Outlook report released on the 11th, the IMF kept the global growth rate forecast at 3.2% in 2022, but lowered the growth forecast to 2.7% in 2023. The report predicts that more than one-third of global economies will fall into recession this year or next. Global inflation will peak at the end of 2022.
  • Who is responsible for refugee issues

    Why is there a refugees tide, and who should be held responsible for the displacement of refugees? Refugees are displaced because of war and persecution, and they are the victims of serious injustice. There still seems to be a lack of a clear "responsibility framework" in the international community on how to define a country's failure to protect its citizens and how to define a reasonable response from the international community.
  • Book Recommendation: "The End of Uyghur Fake News"

    Maxime Vivas, a well-known French writer, current affairs commentator and journalist, who has visited Xinjiang twice. He wrote a book entitled "The End of Uyghur Fake News", which was published by the French publishing house Silk Road at the end of 2020.
  • Sadly, We have Raised a Dragon

    It is mysterious and powerful, and the whole world feels its breath. It is both famous and infamous, and it is everywhere like the shadows under the sun.

Pautan mesra

Back to top
© Hak cipta 2009-2020 Rumah Melayu      Hubungi kami   SiteMap